Jane Street Group LLC Decreases Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Jane Street Group LLC decreased its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 50.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 504,277 shares of the company’s stock after selling 517,256 shares during the quarter. Jane Street Group LLC’s holdings in Adaptive Biotechnologies were worth $2,582,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ADPT. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in Adaptive Biotechnologies in the third quarter valued at $34,000. MQS Management LLC purchased a new stake in Adaptive Biotechnologies during the 2nd quarter worth about $36,000. Rothschild Investment LLC acquired a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth about $36,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 769.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock valued at $48,000 after acquiring an additional 11,852 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. BTIG Research boosted their target price on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $6.39 on Monday. The stock’s 50-day moving average is $5.50 and its two-hundred day moving average is $4.68. Adaptive Biotechnologies Co. has a 1 year low of $2.28 and a 1 year high of $7.07. The firm has a market cap of $943.03 million, a price-to-earnings ratio of -4.77 and a beta of 1.49.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.